Pre-clinical quantitative imaging and mouse-specific dosimetry for 111In-labelled radiotracers

Background Accurate quantification in molecular imaging is essential to improve the assessment of novel drugs and compare the radiobiological effects of therapeutic agents prior to in-human studies. The aim of this study was to investigate the challenges and feasibility of pre-clinical quantitative...

Full description

Saved in:
Bibliographic Details
Published in:EJNMMI research 2016-11, Vol.6 (1), p.85-85, Article 85
Main Authors: Denis-Bacelar, Ana M., Cronin, Sarah E., Da Pieve, Chiara, Paul, Rowena L., Eccles, Sue A., Spinks, Terence J., Box, Carol, Hall, Adrian, Sosabowski, Jane K., Kramer-Marek, Gabriela, Flux, Glenn D.
Format: Article
Language:English
Subjects:
Cardiac Imaging
Imaging
Medicine
Medicine & Public Health
Nuclear Medicine
Oncology
Original Research
Orthopedics
Radiology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background Accurate quantification in molecular imaging is essential to improve the assessment of novel drugs and compare the radiobiological effects of therapeutic agents prior to in-human studies. The aim of this study was to investigate the challenges and feasibility of pre-clinical quantitative imaging and mouse-specific dosimetry of 111 In-labelled radiotracers. Attenuation, scatter and partial volume effects were studied using phantom experiments, and an activity calibration curve was obtained for varying sphere sizes. Six SK-OV-3-tumour bearing mice were injected with 111 In-labelled HER2-targeting monoclonal antibodies (mAbs) (range 5.58–8.52 MBq). Sequential SPECT imaging up to 197 h post-injection was performed using the Albira SPECT/PET/CT pre-clinical scanner. Mice were culled for quantitative analysis of biodistribution studies. The tumour activity, mass and percentage of injected activity per gram of tissue (%IA/g) were calculated at the final scan time point and compared to the values determined from the biodistribution data. Delivered 111 In-labelled mAbs tumour absorbed doses were calculated using mouse-specific convolution dosimetry, and absorbed doses for 90 Y-labelled mAbs were extrapolated under the assumptions of equivalent injected activities, biological half-lives and uptake distributions as for 111 In. Results For the sphere sizes investigated (volume 0.03–1.17 ml), the calibration factor varied by a factor of 3.7, whilst for the range of tumour masses in the mice (41–232 mg), the calibration factor changed by a factor of 2.5. Comparisons between the mice imaging and the biodistribution results showed a statistically significant correlation for the tumour activity ( r  = 0.999, P  
ISSN:2191-219X
2191-219X
DOI:10.1186/s13550-016-0238-z